Park Place Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Park Place Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.26K	Hold	4	–	–	﹤0.01%	1044
2026 Q1	$799	Hold	4	–	–	﹤0.01%	821
2025 Q4	$756	Buy	+4	New	+$769	﹤0.01%	773

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Park Place Capital's LGND Position: Q2 2026 in Review

Park Place Capital held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 4 shares worth $1.26K. The position accounts for ﹤0.01% of the portfolio, ranked #1044.

Park Place Capital first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Park Place Capital held 4 shares of Ligand Pharmaceuticals worth $1.26K as of Q2 2026.
Park Place Capital left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
Ligand Pharmaceuticals made up ﹤0.01% of Park Place Capital's portfolio in Q2 2026, its #1044 holding.
Park Place Capital first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.